Biosimilars Sandoz, the soon to be spun out biosimilars and generic business of Novartis, today released positive results from the MYLIGHT Phase III confirmatory efficacy and safety study for its biosimilar aflibercept, for patients living with wet macular degeneration – a key development in its efforts to address this area of unmet medical need. 15 August 2023